Factory/PlantPharma & medical

JGC completes Chugai Pharma's UT3 biopharmaceutical API facility in Utsunomiya

JGC Holdings CorporationUtsunomiya, TochigiPublished Aug 17, 2026

InvestmentNot disclosed

PhaseCompleted

Start—

CompletionMay 2026

JGC Holdings completed the UT3 biopharmaceutical active pharmaceutical ingredient facility for Chugai Pharmaceutical Industry at its Utsunomiya plant in May 2026. The four-story facility supports clinical-trial manufacturing through initial commercial production and includes continuous-production capabilities, solar panels and other environmental features; it was handed over on May 14, 2026.

Project facts

Owner: JGC Holdings Corporation
Listing: 1963 Tokyo
Facility: Factory/Plant
Sector: Pharma & medical
Location: Utsunomiya, Tochigi, Japan
Investment: Not disclosed
Scale / capacity: 9,966 sqm floor area
Contractor: JGC Corporation
Completion: May 2026
Announced: Jul 7, 2026

Figures and schedules are as announced by the company or the public body concerned; plans can change. Amounts that were not disclosed are recorded as not disclosed, never estimated.

Also in Tochigi4 projects · ¥6B disclosedOn the map →

Ashimori Industry to build sewer-pipeline rehabilitation materials plant in TochigiAshimori Industry Co., Ltd.Planned¥6B Dentas subsidiary to acquire mass-production mold for New KISSYOU ion toothbrushesDentas Co., Ltd.Planned¥32.7M Syla Solar to acquire grid-connected battery storage facility in TochigiSyla Holdings Co., Ltd.Plannedn/d

Latest in Pharma & medicalAll Pharma & medical →

Fujifilm to install ADC raw-material manufacturing equipment at Hirono plant

NewPharma & medicalFukushimaPlanned2026.10.07

Fujifilm will install payload and linker-payload manufacturing equipment, including reaction vessels, a filtration dryer and a preparative HPLC system, at the Hirono plant in Fukushima. The facility will also add a laboratory for process and analytical-method development, with operations scheduled to begin in 2028, enabling Fujifilm's one-stop domestic ADC CDMO service.

Shikoku Chuken to build new headquarters and research facility in Ayagawa

Pharma & medicalKagawaPlanned2026.10.01

Shikoku Chuken will build a new headquarters facility on land adjacent to its existing headquarters in Ayagawa, Kagawa. The facility will expand research and development using clinical specimens and testing data collected from across Shikoku, along with corporate planning, information processing and administrative functions; operations are scheduled to begin in January 2028.

Olympus completes new B Building at Nagano site for medical-device component production

Pharma & medicalNaganoCompleted¥18B2026.08.21

Olympus has completed the new B Building at its Nagano site in Tatsuno, Nagano, consolidating development and manufacturing functions and establishing a production base for key medical-device components. Construction began in February 2025, with full operation targeted for FY2026; the building has 17,665 sqm of total floor area and a total construction cost of approximately ¥18 billion.

Lion to build new pharmaceutical plant in Hung Yen, Vietnam

Pharma & medicalHung YenPlanned¥1.5B2026.08.17

Lion has approved construction of a new pharmaceutical plant through its wholly owned Vietnamese subsidiary Merap Lion. The facility will produce prescription and over-the-counter solid-dose medicines, including tablets and granules, with operations planned to begin in the second half of 2030.